AnHeart Therapeutics Inc.
AnHeart Therapeutics is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Lead asset taletrectinib, a potential best-in-class next-generation ROS1 inhibitor, is in pivotal Phase 2 trials in first-line and second-line patients with ROS1+ NSCLC and has received BTD from both the US FDA and China NMPA. Second asset safusidenib, a potential best-in-class brain-penetrant mIDH1 inhibitor, is in Phase 2 trials in patients with IDH1-mutatnt glioma. The US headquarter of AnHeart is in New York.